2023
Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, Ciplea A, Cooper J, Fabian M, Hale T, Jacobs D, Kakara M, Krysko K, Longbrake E, Marcus J, Repovic P, Riley C, Romeo A, Rutatangwa A, West T, Hellwig K, LaHue S, Bove R. Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Annals Of Clinical And Translational Neurology 2023, 10: 2053-2064. PMID: 37675826, PMCID: PMC10647007, DOI: 10.1002/acn3.51893.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderDisease-modifying therapiesMultiple sclerosisAnti-CD20 monoclonal antibody therapyCD20 IgG1 monoclonal antibodyInfant development outcomesPatient questionnaire responsesRelative infant doseOptica spectrum disorderMonoclonal antibody therapyIgG1 monoclonal antibodyMature breastmilkClinical relapseDisease activityInfant doseMAb therapyInfant outcomesAntibody therapyPostpartum womenPostpartum periodMedical recordsInfant growthPostpartum treatmentNeurological conditionsBreastmilkEarly Treatment for Multiple Sclerosis
Longbrake E, Kalincik T. Early Treatment for Multiple Sclerosis. Neurology 2023, 101: 549-550. PMID: 37468283, DOI: 10.1212/wnl.0000000000207754.Peer-Reviewed Original Research
2022
Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease
Peters J, Longbrake E. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Multiple Sclerosis And Related Disorders 2022, 68: 104400. PMID: 36544307, PMCID: PMC10075342, DOI: 10.1016/j.msard.2022.104400.Peer-Reviewed Original ResearchConceptsLong-term B-cell depletionB-cell depletionReal-world cohortSevere infectionsTotal infectionsSingle-center observational studyEffective disease-modifying therapiesInfectious adverse effectsFormer smoking statusRisk of hospitalizationAutoimmune neurologic diseasesAutoimmune neurologic disordersDisease-modifying therapiesYears of treatmentRate of infectionLong-term useImmunologic changesLaboratory abnormalitiesClinical factorsSmoking statusHigher BMIMultiple sclerosisSerious infectionsNeurologic disordersFemale gender
2021
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease
Money KM, Mahatoo A, Samaan S, Anand P, Baber U, Bailey M, Bakshi R, Bouley A, Bower A, Cahill J, Houtchens M, Katz J, Lathi E, Levit E, Longbrake EE, McAdams M, Napoli S, Raibagkar P, Wade P, Sloane JA. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease. Neurology Neuroimmunology & Neuroinflammation 2021, 8: e1046. PMID: 34341094, PMCID: PMC8362350, DOI: 10.1212/nxi.0000000000001046.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionHospitalization ratesRisk factorsSevere coronavirus disease 2019 (COVID-19) infectionDisease-modifying therapy useCoronavirus disease 2019 (COVID-19) infectionStepwise multivariate logistic regressionCNS Demyelinating DiseaseNausea/vomitingAbsolute lymphocyte countIndependent risk factorNumber of comorbiditiesDisease 2019 infectionPatient risk factorsRisk of hospitalizationCOVID-19 cohortDisease-modifying therapiesCase fatality rateMultivariate logistic regressionCOVID-19 registryFisher's exact testDemyelinating diseaseClinical characteristicsLymphocyte countNeurologic symptoms
2016
The contemporary spectrum of multiple sclerosis misdiagnosis
Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. The contemporary spectrum of multiple sclerosis misdiagnosis. Neurology 2016, 87: 1393-1399. PMID: 27581217, PMCID: PMC5047038, DOI: 10.1212/wnl.0000000000003152.Peer-Reviewed Original ResearchConceptsMultiple sclerosisNeurologic symptomsMisdiagnosis of MSAcademic MS centersCorroborative objective evidenceMultiple sclerosis misdiagnosisDisease-modifying therapiesRadiographic diagnostic criteriaNonspecific neurologic symptomsMS therapyConsideration of symptomsCNS lesionsMRI abnormalitiesMS centersUnnecessary morbidityAlternate diagnosisMS attacksCorrect diagnosisDiagnostic criteriaPatientsMisdiagnosisObjective evidenceSymptomsTherapyDiagnosisEffect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity
Longbrake EE, Cross AH. Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity. JAMA Neurology 2016, 73: 1-7. PMID: 26720195, DOI: 10.1001/jamaneurol.2015.3977.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesB cell immunityB cellsMultiple sclerosisAnti-inflammatory cytokine interleukin-10B-cell-depleting agentsMultiple Sclerosis Disease-Modifying TherapiesMost disease-modifying therapiesCytokine interleukin-10Memory B cellsB cell functionB-cell phenotypeB cell expressionB cell productionNaive B cellsMagnetic resonance imagingB cell precursorsClinical courseTherapeutic trialsInterleukin-10Proinflammatory cytokinesHumoral immunityClinical activityTherapeutic interventionsResonance imagingEfficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
Longbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice. Multiple Sclerosis Journal - Experimental Translational And Clinical 2016, 2: 2055217316677868. PMID: 28280599, PMCID: PMC5340186, DOI: 10.1177/2055217316677868.Peer-Reviewed Original ResearchDisease-modifying therapiesMultiple sclerosis activityInjectable disease-modifying therapiesOral disease-modifying therapiesMultiple sclerosisInjectable therapiesBaseline differencesClinical practiceRetrospective cohort studyProportional hazards modelDrug discontinuationCohort studyDiscontinuation ratesTreatment groupsHazards modelSclerosisPatientsTherapyRelative efficacyTolerabilityFurther studiesHigher proportionEfficacyExpert opinionTreatment
2015
Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH. Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance. Multiple Sclerosis Journal - Experimental Translational And Clinical 2015, 1: 2055217315596994. PMID: 26550483, PMCID: PMC4636217, DOI: 10.1177/2055217315596994.Peer-Reviewed Original ResearchDimethyl fumarateMultiple sclerosisRisk factorsClinical significanceGrade 2Lower baseline absolute lymphocyte countBaseline absolute lymphocyte countSingle academic medical centerDMF-induced lymphopeniaDMF-treated patientsRetrospective cohort studyAbsolute lymphocyte countGood clinical responseProgressive multifocal leukoencephalopathyDisease-modifying therapiesFraction of patientsReal-world populationAcademic medical centerLymphocyte monitoringNatalizumab exposureMultifocal leukoencephalopathyClinical responseCohort studyLymphocyte countOlder patients